SecBot SecBot
8-K ·Filed Aug 14, 2026

SKYE

Skye Bioscience, Inc.
MIXED
Impact 7/10
Horizonmonths Processed3mo ago SEC0001628280-26-056966
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ◆ Mixed

This reverse merger fundamentally alters Skye's business, shifting focus to Redx's pipeline. Current SKYE shareholders face significant dilution and a change of control. Monitor the proxy statement for detailed exchange ratio calculations and the timeline for shareholder votes. The stock's reaction will depend on investor perception of Redx's pipeline value versus the dilution and CVR structure.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.5015
T+0 close · Aug 14, 2026 · via day close
Latest settled
−82.80%
T+60 · $0.0862
Vs SPY
−79.76%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $0.5015entry
  2. T+1 · 3mo ago −17.23%α −16.76% · $0.4151
  3. T+5 · 3mo ago −44.17%α −42.80% · $0.2800
  4. T+20 · 2mo ago −50.40%α −48.41% · $0.2487
  5. T+60 · 8d ago −82.80%α −79.76% · $0.0862

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Skye Bioscience (SKYE) entered into a definitive transaction agreement to acquire Redx Pharma Limited via a scheme of arrangement. The deal values Redx at $161 million and includes a concurrent PIPE of $125 million (with a $68 million tranche from the Securities Purchase Agreement). Skye will issue shares to Redx shareholders based on an exchange ratio, and existing Skye stockholders will receive contingent value rights (CVRs). The transaction constitutes a change of control of Skye, with Redx designating the post-closing board and management. A 1-for-8 reverse stock split was filed to regain Nasdaq compliance. The filing is a transformative reverse merger that fundamentally changes Skye's business and capital structure, making it a significant event for current SKYE shareholders who will see their ownership diluted and the company's direction shift to Redx's pipeline.

Key Financial Metrics

Deal Value
$161.0M
Deal Type
merger
Offering Size
$125.0M

Key Facts

  • Skye Bioscience (SKYE) agreed to acquire Redx Pharma Limited in a reverse merger valued at $161 million for Redx.
  • A concurrent PIPE of $125 million is planned, with a $68 million tranche documented in a Securities Purchase Agreement.
  • The transaction constitutes a change of control of Skye, with Redx designating the post-closing board and management.
  • Existing Skye stockholders will receive one contingent value right (Acquiror Legacy CVR) per share held pre-closing.
  • A 1-for-8 reverse stock split was filed on August 12, 2026, effective August 24, 2026, to regain Nasdaq compliance.
  • The deal is subject to shareholder approvals from both Skye and Redx, court sanction, and other customary conditions, with an end date of August 14, 2027.

Financial Impact

Redx valued at $161M; PIPE of $125M ($68M tranche documented); Skye's pre-money equity value set at $14.5M with a $2M target net cash adjustment.

dilutionownershipvaluation

Risk Factors

  • Shareholder approval may not be obtained from either Skye or Redx stockholders.
  • The transaction may not close by the August 14, 2027 end date.
  • Integration risks and potential value destruction from the reverse merger structure.
  • The CVRs for existing Skye stockholders may have no value.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
77% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-056966
Exhibit: ex031-skyebioscienceincx.htm0001628280-26-056966
Document: skye-20260814xex106xpipese.htm0001628280-26-056966

Track record

16 reports on SKYE

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +82.80% at T+60 after the Aug 14, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago DEFA14A Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  2. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $1.08 Now $1.07 −1.39% settles Dec 11
  3. Oct 26, 202621d ago PREM14A Bearish 7/10 Entry $1.45 Now $1.07 +26.55% settles Nov 24
  4. Oct 14, 20264w ago SC 13G Neutral 4/10 Entry $1.59 to $1.08 Now $1.07 −33.02% ▼ −32.08% −30.17% vs SPY
  5. Sep 24, 20267w ago Insider Cluster Neutral 3/10 Entry $1.67 to $1.54 Now $1.07 −36.23% ▼ −7.78% −6.31% vs SPY
  6. Sep 24, 20267w ago SC 13D/A Bearish 6/10 Entry $1.67 to $1.54 Now $1.07 +36.23% ▲ +7.78% +6.31% vs SPY
  7. Sep 18, 20268w ago Insider Cluster Bearish 4/10 Entry $1.78 to $1.53 Now $1.07 +40.17% ▲ +14.04% +13.14% vs SPY
  8. Aug 19, 202612w ago DEFA14A Neutral 4/10 Entry $0.2809 to $0.2206 Now $1.07 +279.14% ▼ −21.46% −21.34% vs SPY
  9. Aug 14, 202613w ago 8-K Mixed 7/10 Viewing Entry $0.5015 to $0.2487 Now $1.07 +112.36% ▼ −50.40% −48.41% vs SPY
  10. Aug 14, 202613w ago Press Release Bearish 7/10 Entry $0.5015 to $0.2487 Now $1.07 −112.36% ▲ +50.40% +48.41% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026